BWC0977

BWC0977 (compound 13) (0.03-2 μg/mL) formic strongly inhibits the growth of multidrug-resistant Gram-negative and Gram-positive bacteria, with an MIC₉₀ range of 0.03-2 μg/mL^[1].
BWC0977 (0.015-40 μg/mL; up to 10 hours) formic exhibits time-dependent bactericidal activity against clinical isolates of E. coli, A. baumannii, K. pneumoniae, and P. aeruginosa^[2].
BWC0977 (0.1 nM-1 mM; 40 min) formic potently inhibits the supercoiling activity of wild-type E. coli DNA gyrase, with an IC₅₀ of 4 nM^[4].
BWC0977 (200 μM; 8 h) formic acts via intercalation and specific interactions with ParC residues D79, M118 and R119^[4].
BWC0977 (0.01-7.5 μg/mL; 16-18 h) formic inhibits the growth of wild-type E. coli MG1655, with an MIC of 0.03 μg/mL^[4].
BWC0977 (0.007-1 μg/mL; 16-18 h) formic exhibits potent antibacterial activity against a variety of drug-susceptible and multidrug-resistant Gram-positive and Gram-negative bacterial isolates^[4].
BWC0977 (pre-incubated at 24°C for 10 min; reacted at 37°C for 40 min) formic potently inhibits the supercoiling activity of E. coli DNA gyrase and the decatenation activity of topoisomerase IV^[3].
In automated patch-clamp assays, BWC0977 (6-point serial dilutions up to 300 μM; 2 min) formic inhibits hERG ion channel activity with an IC₅₀ of 131 μM, while in manual patch-clamp assays, the IC₅₀ is 49.7 μM^[3].
BWC0977 formic is a substrate of human MATE2-K and OAT3 transporters, with K_m values of 469 μM and 121 μM, respectively^[3].
BWC0977 (> 200 μM) formic exhibits over 5000-fold higher selectivity for bacterial type II topoisomerases than for human topoisomerase IIα and IIβ. Its IC₅₀ against human topoisomerase IIα is 113 μM, and no detectable inhibitory effect on human topoisomerase IIβ is observed at the highest concentration of 200 μM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .